Exploration of candidate genes responsible for esophageal squamous cell carcinoma (ESCC) pathogenesis may provide insight into the underlying signaling pathways to uncover novel therapeutic targets.
The ATR-CHK1 pathway plays a critical role as a replication checkpoint and is a promising target for emerging therapies.
Starting with a bioinformatics approach using publicly available databases, the authors were able to confirm that tissues from patients with lung adenocarcinoma had increased expression of BCCIP and that high expression levels of BCCIP were correlated with poor patient prognosis.
Solid tumor biology has become a critical step in accessing the potency of many cancer drugs. 3D spheroids and organoids can provide measurements such as size differences under drug conditions or metabolism and diffusion rates critical to drug development.
The development of targeted molecular therapies is an increasingly popular approach to combat and overcome the limitations of conventional treatments.
A fundamental understanding of the molecular mechanisms responsible for the development and progression of RCC will be pivotal in developing next-generation treatment protocols to improve patient outcomes.
